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Abstract Timolol maleate (TM) has been used for many
years for the reduction of intraocular pressure (IOP) in
glaucoma patients. However, the topical mode of admin-
istration (eyedrops) is far from optimal because of the
issues of low bioavailability, high drug wastage, and
lack of patient compliance. Suboptimal control of the
IOP leads to disease progression and eventually to
blindness. Ideally, TM is delivered to the patient so that its
action is both localized and sustained for 3 months or more. In
this work, we developed a subconjunctival TM microfilm for
sustained, long-term delivery of TM to the eyes, using the
biodegradable elastomer poly(lactide-co-caprolactone)
(PLC). The copolymer is biocompatible and has flexibility
and mechanical characteristics suitable for a patient-
acceptable implant. Controlling the release of TM for 3months
is challenging, and this work describes how, by using a com-
bination of multilayering and blending with poly(ethylene
glycol) (PEG) copolymers, we were able to develop a
TM-incorporated biodegradable film that can deliver
TM at a therapeutic dose for 90 days in vitro. The data was
further confirmed in a diseased primate model, with sustained
IOP-lowering effects for 5 months with a single implant, with
acceptable biocompatibility and partial degradation.
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Introduction
Glaucoma is a progressive optic neuropathy that is character-
ized by characteristic changes to the optic nerve and visual
field loss. Glaucoma is an age-related eye disease and affects
60.5 million people worldwide [1]. According to the World
Health Organization (WHO) statistics, glaucoma is the second
leading cause of blindness in the world [2]. Based on the
projected expansion of the aging population, it is estimated
that by 2020, glaucoma would affect about 80 million people,
leaving close to 11 million bilaterally blind [1]. This will in-
evitably result in the loss or productivity, as well as in cost for
the healthcare system as a whole.
Although glaucomatous syndromes could be categorized
as normal-tension glaucoma (NTG) and high-tension glauco-
ma (HTG), the elevation of intraocular pressure (IOP) is the
major modifiable risk factor of glaucoma and, if left untreated,
results in disease progression in 70 % of all glaucoma cases
[3]. According to the Early Manifest Glaucoma Treatment
trial, for every 1-mmHg reduction in IOP, the risk of glaucoma
progression is decreased by 10 % [4]. One of the most widely
used medical treatments is timolol maleate (TM) eyedrops.
Timolol, which was approved by the FDA in 1979 [5], is a
beta-adrenergic receptor antagonist that reduces the IOP by
decreasing the production of aqueous humor [5]. Beyond its
excellent IOP-lowering efficacy, the effectiveness of the treat-
ment outcome is variable and highly dependent on patient
compliance. One recent clinical survey observed that nearly
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80 % of the patients who are diagnosed with glaucoma
discontinued the treatment via eyedrops after 1 year, and this
number increased to ∼90 % after 3 years [6]. Moreover, this
mode of administration is suboptimal because of low bioavail-
ability of the drug, caused by rapid elimination in the pre-
corneal area via lacrimation, tear drainage, and turnover.
Sustained drug delivery offers the best alternative to over-
come low drug bioavailability and drug fluctuation issues and
helps eliminate the issue of patient compliance. Beyond patient
convenience and compliance, greater therapeutic efficacy could
be achieved. Efforts to develop such TM delivery systems have
been ongoing, and a number of different systems have emerged.
They include fornex inserts [7], hydrogels [8], contact lenses
[9–11], nano-fiber [12], and microspheres [13]. However, these
systems have not made it to the clinic primarily because they
lack sustained release: the typical release period is a few hours
to days [7–12] and does not extend to a month or more.
Recently, Bertram et al. reported a blend microsphere system
that achieved long-term release of TM [13] via subconjunctival
injection; however, there was little discussion of the daily
targeted dose and whether it was achieved. Moreover, due to
the fairly large particle size and relatively low drug loading in
the microspheres, it is likely that the required volume per injec-
tion is substantial. Hence, to date, there is no viable TM deliv-
ery system that can be readily translated for clinical use.
Therefore, the goal of this work is to develop a timolol deliv-
ery system that allows placement in the subconjunctiva while
delivering timolol in a consistent and controlled manner.
Timolol is typically administrated via eyedrops twice a day as a
0.25 % formulation, which amounts to a daily dose of about
250 μg. The bioavailability of timolol delivered through eye-
drops is only about 1–2 %, indicating that the effective daily
dosage required is 2.5–5 μg/day. In this work, we evaluated the
release of timolol maleate from microfilms composed of
poly(lactide-co-caprolactone) (PLC)- and poly(ethylene glycol)
(PEG)-based copolymers, with the focus of achieving the
targeted daily dosage of ∼2.5 μg for 3 months. The
subconjunctival implantation of this microfilm is done in a min-
imally invasive mode that will be patient acceptable. We believe
this work is by far the longest sustained delivery of timolol re-
ported to date, achieving the targeted daily dose. To verify the
in vitro to in vivo translatability, the implant was inserted into the
subconjunctival space of primate eyes and was shown to be safe
and efficacious for up to 5 months. The results suggest strongly
that this system offers a paradigm shift in treating glaucoma.
Materials and methods
Materials
Granular 70:30 poly(lactide)/poly(ε-caprolactone) copolymer
(PLC, Purac), poly(ε-caprolactone)/poly(ethylene glycol)
(PCL-PEG, Advanced Polymer Materials Inc.), timolol male-
ate salt (TM, Sigma), timolol base (TB, Nivon Pharma), phos-
phate buffer saline tablets (pH 7.4, PBS, Sigma), and ammo-
nium acetate (Sigma-Aldrich) were used as received.
Dichloromethane (DCM, Tedia Chemical Company Inc.),
acetonitrile (ACN, Tedia Chemical Company Inc.), methanol
(MeOH, Tedia Chemical Company Inc.), and triethylamine
(TEA, Sigma-Aldrich) used were of HPLC grade.
Film preparation
Single layer TM or TBwas first dispersed/dissolved in DCM
followed by the addition of polymeric pellets at 1 g polymer to
5 mL DCM ratio. The mixture was stirred overnight to obtain
a homogenous TM/TB-loaded polymer solution. The solu-
tions were cast onto a glass plate and dried under ambient
conditions overnight before drying in a vacuum oven at
37 °C for 1 week. The preparations were conducted in the
absence of light due to the light sensitivity of TM and TB.
All the formulations are listed in Table 1.
Multilayer TM was first dispersed in DCM followed by the
addition of polymeric pellets at a 1 g polymer to 5 mL DCM
ratio. The mixture was stirred overnight to obtain a homoge-
nous TM-loaded polymer solution. A blank polymer solution
was prepared in a similar manner. The blank polymer solution
was first cast onto a glass plate, followed by the TM-loaded
polymer solution on top of the first blank polymer layer and a
final blank polymer solution on top of the TM-loaded layer at
3-min intervals. The dry thickness of the film is well correlat-
ed to the wet thickness of the film as long as factors such as
drying environment, casting rate, casting platform, and poly-
mer solution concentration are kept constant. The wet thick-
ness of the film was adjusted such that the dry thickness is
about 15 μm for the two blank layers and about 10 μm for the
TM-loaded layer. The multilayered films were dried under
ambient conditions overnight before drying in a vacuum oven
at 37 °C for 1 week. The preparations were conducted in the
absence of light due to the light sensitivity of TM. Finally, the
thickness of the film was measured using the Elcometer 456.
All the formulations are listed in Table 2.
In vitro release studies
In vitro release studies were conducted by incubating the films
of 10×10 mm at 37 °C in glass bottles, each containing 3 mL
of buffer solution (pH 7.4). At each sample retrieval time
point, the release medium was completely removed and re-
placed with fresh buffer to maintain sink condition. The TM
and TB concentrations in the release medium were analyzed
using reversed-phase higher performance liquid chromatogra-
phy (RP-HPLC). TM analysis: An Agilent Zorbax Eclipse
XDB C-18 column (4.6×250 mm, 5 μm) was connected with
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a Dionex 3000-RS equipped with a diode array detector
(DAD). Mobile phase 25:75 volume ratio of ACN/20 mM
ammonium acetate was used where the pH of the mobile
phase was adjusted to pH 5.2 with acetic acid. Other operating
conditions were as follows: flow rate=1 mL/min, sample vol-
ume=10μL, column temperature=30 °C, and detector=
294 nm. TB analysis:AnAgilent Zorbax Extend C-18 column
(4.6×250 mm, 5 μm) was connected with a Dionex 3000-RS.
Mobile phase 30:70 volume ratio of 20 mM TEA/methanol
was used. Other operating conditions were as follows: flow
rate=1 mL/min, sample volume=10 μL, column tempera-
ture=30 °C, and detector=299 nm. All samples were prepared
and tested in triplicates while the data is presented as mean±
standard deviation of the mean.
Polymer degradation
The degradation of polymers was characterized in terms of the
changes in mass and molecular weight. Films of 10×10 mm
dimensions were immersed in buffer solution (pH 7.4) and
incubated at 37 °C. The buffer was refreshed weekly and at
every predetermined time point; some films were removed
from the buffer, rinsed with deionized water, and dried in a
37 °C vacuum oven for at least 7 days. The mass of the dried
samples was measured followed by molecular weight mea-
surement using a gel permeation chromatography (GPC,
Agilent 1100) equipped with refractive index detector (RID).
Fifty microliters of the degraded polymer samples in chloro-
form was injected through an Agilent PLGel MIXED-C col-
umn (300×7.5 mm) under a constant chloroform flow rate of
1 mL/min at 35 °C. The molecular weight of the samples was
obtained relative to a calibration curve from polystyrene stan-
dards (Mw between 165 and 5000 g/mol).
Film sterilization for in vivo studies
All samples were sterilized using ethylene oxide at 37 °C for
24 h prior to insertion into monkeys.
Table 1 Compositions of the
single-layer films Sample name Polymer ratio (%) Drug loading
(wt% of total film)
Thickness
(μm)
PLC PCL (10 k)-PEG (5 k) TM TB
PLC – – – – 40
PLC 1% TB 100 – – 1 40
PLC 5% TB 100 – – 5 40
PLC 1% TM 100 – 1 – 40
PLC 5% TM 100 – 5 – 40
90:10 PLC/PCL-PEG 1% TM 90 10 1 – 40
80:20 PLC/PCL-PEG 1% TM 80 20 1 – 40
90:10 PLC/PCL-PEG 5% TM 90 10 5 – 40
80:20 PLC/PCL-PEG 5% TM 80 20 5 – 40
Table 2 Compositions of the
multilayered films Sample name Layer Schematic Drug loading
(wt% of total film)
Dry thickness
(μm)
Sandwich PCL (10 k)-PEG
(5 k) 5% TM
1 PLC – 15
2 5 % timolol maleate in
80:20 PLC/PCL
(10 k)-PEG (5 k)
5 10
3 PLC – 15
Sandwich PCL (10 k)-PEG
(5 k) 20 % TM
1 PLC – 15
2 20 % timolol in
80:20 PLC/PCL
(10 k)-PEG (5 k)
20 10
3 PLC – 15
Sandwich PCL (10 k)-PEG
(1 k) 20 % TM
1 PLC – 15
2 20 % timolol in
80:20 PLC/PCL
(10 k)-PEG (1 k)
20 10
3 PLC – 15
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Animal study: monkey model of glaucoma
Experimentation on non-human primates (Macaca
fascicularis) was performed in accordance with the statement
for the use of animals in ophthalmic and vision research ap-
proved by the Association for Research in Vision and
Ophthalmology. The guidelines of the Animal Ethics
Committee of the SingHealth Singapore Association for
Assessment and Accreditation of Laboratory Animal Care
(International-accredited) were also satisfied. Non-human pri-
mates were anesthetized by intramuscular injection of keta-
mine (20 mg/kg body weight) and acepromazine maleate
(0.25 mg/kg body weight). Their airway, respiration, and
pulse were monitored during all procedures. One to two drops
of 1 % xylocaine were used as topical anesthesia to reduce
possible discomfort to the animals involved during the
procedure.
Nine non-human primates were used in this study
and were divided into two groups: group 1, high-intra-
ocular-pressure (hypertensive) monkeys (n=6) received a sin-
gle subconjunctival implantation of 4 mm×6 mm timolol mi-
crofilm into both eyes, and group 2, hypertensive monkeys
(n=3) received twice-daily timolol eyedrops into both eyes for
28 days.
Subconjunctival implantation of timolol microfilms
in non-human primates
This procedure was performed under aseptic conditions
in a surgical theater equipped for non-human primates.
The group 1 non-human primates received a subconjunctival
implant with timolol-loaded microfilm. In brief, a limited con-
junctival dissection was performed and then a microfilm was
inserted; it was sutured 2 mm posterior to the limbus and
secured with two 10/0 nylon sutures. Topical tobramycin oint-
ment 1 % was administered to the operated eye daily for
5 days.
Intraocular pressure monitoring and clinical examination
For IOP measurements, the non-human monkeys were lightly
anesthetized with ketamine at 5 mg/kg body weight. The top-
ical anesthesia was applied as mentioned above. IOP was
measured via tonometer (Tono-Pen® XL, Reichert
Technologies, Depew, NY) at 2–4 p.m. weekly for 1 month,
and biweekly for the second month and every month for an-
other 2 months. The procedure took about 5 min for each
monkey. Once daily baseline IOP measurements to both eyes
of all animals for three consecutive days were recorded prior
to the commencement of the treatment at 2–4 p.m. Six to eight
IOP measurements were taken to ensure an average IOP mea-
surement is attained each time. The treatment was commenced
on day 4.
Clinical examinations
Non-human primates were anesthetized, and visual inspection
of all eyes after injections, or topical administration, was done
every day for signs of conjunctival irritation, inflammation, or
infection at the injection site. Slit lamp microscopic examina-
tion of the exterior, anterior chamber, and posterior chamber
of the eyes was performed before the injections and weekly
thereafter. The monkeys were also monitored for any gross
changes such as eye discharge, squinting, or abnormal behav-
ior suggesting pain or severe discomfort.
Mathematical model
The power law model [14, 15] is a semi-empirical equation
used to describe drug release from polymeric systems. The
model describes a biphasic release, a fast initial release due
to desorption followed by a diffusion-controlled release as can




where b represents the initial (sometimes called the Bburst^
release) by desorption, a represents a constant that is governed
by structure and geometric characteristics, and n is an expo-
nent that is related to the mechanistic details of the release: at
the Fickian limit, the value of n is 0.5 for thin films. For this
work, single-layered formulations were fitted to the equation.
Since the formulations are monolithic matrices, n is expected
to be close to 0.5 in this case.
Statistical analysis
Significance was set at the 0.05 level. SPSS version 19 (IBM
SPSS Statistics, Chicago, USA) was used for all analyses.
Results and discussion
Currently, topical application of timolol remains the most
common treatment option for reducing IOP in glaucoma and
ocular hypertension patients. Topical administration of medi-
cal eyedrops is suboptimal and involves high wastage of the
drug, and cannot be sustained for more than a few hours.
Therefore, for chronic conditions, poor patient compliance is
a major challenge. Although there is a lot of dissatisfaction
with the eyedrop timolol treatment, there is no breakthrough
in treatment options due to the stringent dose requirements
over long periods; where sustained delivery has been reported
in in vitro studies, there is no convincing in vivo data to show
enhanced duration of action. Hence, in this work, we report on
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the development of a Bsoft^ microfilm that can deliver the
dose of 2.5 μg of timolol daily for several days. The elastomer
PLC was chosen as the main microfilm matrix because it is
biocompatible and our laboratory has demonstrated its use in
ocular biomedical devices [16–18]. Moreover, the eventual
degradation of this copolymer into harmless by-products
would eradicate the need for removal surgery.
Strategies to control burst release
In order to achieve sustained delivery for 3 months, the fol-
lowing strategies were pursued:
(a) Use of the base form of TM to enhance lipophilicity and
thus sustain its release longer
(b) Blending of PLC with PEG copolymers to reduce burst
effects and to sustain release, especially for high drug
loading
(c) Use of a sandwich film, i.e., three-layered film with the
drug-incorporated layer in the middle to minimize burst
and sustain release
Effects of drug form
Timolol drugs exist in two forms—an esterified form known
as timolol maleate, TM, and a Bbase^ form known as timolol,
TB. In the usual case of amine-based drugs, the base form is
considered more lipophilic than the salt form; consequently,
the burst effect of the drug (from lipophilic matrices such as
PLC) is less when the drug is in the base form, as it is more
soluble.
Contrary to this expectation, Fig. 1a shows that the TB-
loaded films showed faster overall release kinetics, including
a substantially higher burst, compared to the TM-loaded films.
The 1 and 5 % TB-loaded films released 34 and 70 % on day
1, and both displayed inopportune termination of release with-
in 2 weeks and 1 week, respectively. On the other hand, the 1
and 5 % TM-loaded films showed more sustained release
(beyond 2 weeks) compared to TB formulations due to
lowered burst (Fig. 1b).
The reason for the higher burst amount (as designated by
the magnitude of b in the fitting of the diffusion equation, in
Fig. 1c) is that the TM is actuallymore lipophilic than TB. The
reported value of the octanol/water partition coefficient for TB
is 2.4 [19], while that for TM is about 60 [20]. This being the
case, we used the more lipophilic TM for the rest of the
studies.
Effects of blending
Based on the above results, TM was selected as the drug form
for optimization of release, and the matrix composition was
further manipulated to get reduced burst and more linear re-
lease profiles. To modulate the burst release, PLC films were
blended with PEG-based copolymers—PCL-PEG. This co-
polymer was chosen based on the hypothesis that the hydro-
phobic segments of the copolymer (PCL segments) could in-
teract with the bulk matrix (PLC) and the hydrophilic segment
of the copolymer could interact with TM to moderate the
release (Fig. 2).
Again, contrary to expectation, the release was actually
higher for the blended than the neat film (Fig. 3a).
Moreover, the burst release increased with increasing blending
ratio (for example, the 10 % PCL-PEG blend formulation had
a burst release of 9.3 % while the 20 % PCL-PEG blend had
15.8 % release on day 1). Following the initial release, the
20 % PCL-PEG blend showed average daily release amounts
of 0.7±0.6 μg for 76 days (Fig. 3b).
The fact that the blending of PLC with PCL-PEG did not
effectively suppress the burst effect may be explained as fol-
lows: the idea behind the use of the PEG copolymer is to
disperse the undissolved drug better in the matrix material, by
interaction of the drug with the PEG segment and better an-
choring through the presence of the attached PCL [21, 22]. At a
PEG molar mass of 5000 Da, the segregation appears to be
worse in that the blending forces more TM to the surface: this
is either due to the higher-than-expected lipophilicity of TM
and/or lesser interaction of the TM with the PEG component.
As we will see in a subsequent section (BIn vivo evaluation^),
lowering themolar mass of the PEG block to 1000Da results in
better dispersion of the drug and leads to an almost linear pro-
file, especially in a three-layer construct.
Since none of the 1 % loaded TM formulations meet the
targeted dose of 2.5 μg/day, we investigated a higher drug
loading of 5 % (Fig. 4a, b). Indeed, increasing the loading
did increase the daily TM release, where 1.4±1.4 μg/day of
TM release was observed in the 20 % PCL-PEG blended
formulation for 80 days. However, increasing the drug loading
also greatly magnified the burst release, where drug release in
the range of 90±9.5 μg/day was observed on day 1 for all the
5 % TM-loaded formulations (Fig. 4b). The burst is possibly
aggravated by the increased drug loading, which leads to
phase-separated drug at the surface [23].
Based on the substantial burst effects seen at 5 % drug
loading, it appears that a monolithic construct with the drug
dispersed in a PLCmatrix with or without the PEG copolymer
would not be able to sustain release over a long period, which
led us to pursue the use of Bsandwich^ constructs coupled
with the use of a more selective compatibilizer in the follow-
ing section.
Effects of a multilayered construct and polymer chain length
Tominimize the burst release, we investigated the use of drug-
free barrier layers to sandwich the drug-loaded layer. As is
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evident from the results (Fig. 5), the introduction of the
Bsandwich^ structure notably reduced the burst approximately
ten times compared to the monolithic structure (Fig. 5a). It
was also interesting that a zero-order release was observed,
whereby the sandwich formulation released 2.1±2.1 μg/day
for 60 days following the initial release on day 1 (Fig. 5b).
However, the introduction of the drug-free barrier layer also
greatly limits the drug for loading, resulting in failure to
achieve the desired target duration of 3 months.
Naturally, the increment in the thickness of the drug-loaded
layer would extend the drug release period without drastically
altering the release too much. But the subconjunctiva contains
numerous small and fragile blood vessels [16–18] and increas-
ing the dimensions of microfilmsmay potentially compromise
patient safety, which is undesired. Hence, an increase in drug
loading to 20 % was evaluated. Figure 6 shows the effects of
polymer chain length in 20 % TM formulations blended using
PCL-PEG with a 5-k PEG segment (Fig. 6a, b). The copoly-
mer formulation with the 5-k PEG segment showed a burst
release of 80 % on the first day. It appears that the barrier
layers were not effective in limiting the burst release at the
very high drug loading, due to the lack of anchorage of the
drugs within the drug-loaded layer, and the resultingmigration
of the drug to the drug-free layers. Theoretically, the barrier
layer could be strengthened by increasing the thickness and
therefore increasing the diffusion distance for the drug to exit
[24, 25]. However, for our work, it is impractical to increase
the thickness of the barrier layer because the final thickness of
the microfilm is only a mere 40 μm and the current barrier
layers are already 15 μm in thickness each.
Fig. 2 Percentage mass loss and molecular weight change of PLC neat film, 1 % TM, 1 % TB, 5 % TM, and 5 % TB PLC formulations. aMass loss. b
Molecular weight change over 8 weeks
Fig. 1 Release profile of 1 % TM, 1 % TB, 5 % TM, and 5 % TB PLC formulations. a Cumulative release of TM- and TB-loaded films. b Amount of
TM/TB released each day. c Compilation of parameters upon fitting to the power law
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We believe that a lower molar mass of the PEG segment
results in better drug dispersion and a more stable co-
localization of the drug in the reservoir matrix. Indeed, in the
formulation blended with the 1-k PEG segment copolymer,
the burst release was effectively suppressed by the barrier
layer (Fig. 6c). Furthermore, from this formulation, we
achieved the desirable zero-order release with approximately
2.7 μg of daily TM release for 3 months (Fig. 6d). Indeed, the
use of the copolymer with shorter PEG segment in the drug-
loaded layer along in a sandwich construct was effective in
retarding the burst and modulating the release. As alluded to
earlier, the effective suppression of burst by the drug-free layer
in the 1-k PEG segment formulation can be attributed to this
factor: the lower PEG molar mass may also allow for better
dispersion of the PEG copolymer phase within the PLC ma-
trix, due to a lesser mismatch between the copolymer and
matrix. It should be noted that the release profiles remain
unchanged after storage for 4 months at ambient conditions,
in a dessicator.
This formulation (sandwich 80:20 PLC/PLC-PEG (1 k)
20 % TM-loaded formulations) gave an excellent zero-order
release while attaining the daily therapeutic dose over several
days. Since this formulation more than adequately matches
our requirements, it was selected for further in vivo
evaluation.
In vivo evaluation
To confirm whether the extended duration of release translates
to longer efficacy of action, we evaluated the safety and effi-
cacy of TM-loaded microfilms in ocular hypersensitive non-
human primates [26]. Since IOP is the key modifiable risk
factor in glaucoma, the IOP reduction following
subconjunctival injection of TM-loaded microfilm was com-
pared to the IOP reduction achievable with daily topical ad-
ministration of TM (eyedrops). Topical treatment using
0.25 % of TM for 28 days showed effective reduction of
IOP during the treatment period (Fig. 7a). The topical treat-
ment used in this work matches the current regimen used by
glaucoma patients [27, 28]; hence, effective IOP reduction
was expected. However, after cessation of treatment, the IOP
returned to the hypertensive baseline IOP after a few weeks
following a washout effect from the eyedrop medication. In
the TM microfilm group, the IOP was suppressed for the en-
tire duration of the experimental period of 140 days (Fig. 7a).
Fig. 3 Release profiles of neat PLC, 80:20 PLC/PCL-PEG, and 90:10 PLC/PCL-PEG of 1 % TM-loaded formulations. a Cumulative release of TM. b
Amount of TM released each day
Fig. 4 Release profile of neat PLC, 80:20 PLC/PCL-PEG, and 90:10 PLC/PCL-PEG of 5 % TM-loaded formulations. a Cumulative release of TM. b
Amount of TM released each day
Drug Deliv. and Transl. Res. (2015) 5:469–479 475
Fig. 5 Release profile of homogenous 80:20 PLC/PLC-PEG and
sandwich of PLC- 80:20 PLC/PCL(10k)-PEG(5k) -PCL 5 % TM-loaded
formulations. aCumulative release of TM. bAmount of TM released each
day; schematic cartoon of c homogenous 80:20 PLC/PLC-PEG and d
sandwich of PLC- 80:20 PLC/PCL(10k)-PEG(5k) -PCL 5 % TM-loaded
formulations
Fig. 6 Release profile of sandwich 80:20 PLC/PLC-PEG (5 k) 20 %
TM-loaded formulations. a Cumulative release of TM. b Amount of
TM released each day. c Schematic of construct and release profile of
sandwich 80:20 PLC/PLC-PEG (1 k) 20 % TM-loaded formulations. d
Cumulative release of TM. e Amount of TM released each day. f
Schematic of construct
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To evaluate the IOP-lowering effects, the percentage reduc-
tion of IOP is presented in Fig. 8b. The daily TM dosing
showed an IOP decrease of 45.8±6.3 % between day 1 and
56; subsequently, IOP reduction plummeted to 1.6±12.3 %
between day 56 and 140 (Fig. 8b). In the TMmicrofilm group,
percentage IOP reduction was 50.1±8.5 % throughout
140 days of the experiment. Further analysis was performed
to compare the IOP reduction at each time point, and the TM
Fig. 7 Comparison between groups with TM eyedrop treatment and TM implant treatment. a Intraocular pressure (IOP) and b percentage reduction of IOP
Fig. 8 a Slit lamp photographs of
subconjunctivally implanted TM
microfilms and the eyedrop
treatment group at 1 month,
3 months, and 5 months after
treatment. b Implant was noted at
0 day, 1 month, 3 months,
5 months, and 8 months after
insertion
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microfilm group displayed significant IOP reduction. The
changes in IOP between the topical administration and TM
microfilm were compared, and the analysis showed statistical
significance over the treatment time (P<0.005), suggesting
that the TM effectively reduces the IOP compared to the top-
ical administration (P<0.005). In addition, from the slit lamp
examinations in Fig. 8a, b, there is no evidence of protrusion
or dislocation of the microfilm in the eyes. There were also no
signs of infection, neovascularization, or bleeding at the sites
of insertion. In this work, we did not observe any TM side
effects in the monkeys used in this study. However, it is im-
portant to note that systemic adsorption of TM has also been
reported to cause respiratory and cardiovascular side effects
[29, 30] including nocturnal hypotension, bradyrhythmias,
and bronchospasm in patients. Other ocular-related side
effects such as unexplained deep orbital pain, blurred
vision [31], and eye redness in patients [32] have also
been reported.
The encouraging in vivo results indicate that TM micro-
films offer a significantly improved treatment option in glau-
coma management. It should be noted that the in vivo effects
(5 months) lasted longer than the in vitro release (ap-
proximately 3 months). There is a possible explanation
for longer in vivo effects (5 months) when compared to
in vitro release (approximately 3 months). It is likely that the
clearance from the subconjunctival space is slower than the
in vitro Bclearance^ (i.e., daily replenishment of release medi-
um). Nevertheless, it is evident that we have developed a TM
sustained-release microfilm that is safe and effective in low-
ering IOP for 5 months in vivo.
Conclusion
By using a combination of multilayering and blending with
PEG copolymers, we were able to develop a timolol maleate-
incorporated biodegradable film that can deliver TM at
a therapeutic dose for 90 days in vitro. In primates with
ocular hypertension, the film provided sustained IOP
lowering for up to 150 days. This study therefore presents
a TMmicrofilm that can provide a significantly different ther-
apeutic option for glaucoma management, surmounting the
challenges of patient non-adherence to the cumbersome topi-
cal regimen.
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